07.09.17: Not intended for U.S. and UK Media

Bayer submits marketing authorization application for BAY94-9027 for the treatment of Hemophilia A in the EUPivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervalsmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news